Wave Life Sciences, Inc.
For the period ended Sep 30, 2026. Filed Oct 27, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Exhibit Description | Filedwith thisReport | Incorporated byReference hereinfrom Form orSchedule | FilingDate | SECFile/Reg.Number |
|---|---|---|---|---|---|
| 3.1 | Amended and Restated Certificate of Incorporation of Wave Life Sciences, Inc., adopted as of August 6, 2026. | Form 8-K12B(Exhibit 3.1) | 8/7/2026 | 001-37627 | |
| 3.2 | Amended and Restated Bylaws of Wave Life Sciences, Inc., adopted as of August 7, 2026. | Form 8-K12B(Exhibit 3.2) | 8/7/2026 | 001-37627 | |
| 10.1 | Form of Indemnification Agreement. | Form 8-K12B(Exhibit 10.1) | 8/7/2026 | 001-37627 | |
| 10.2 | Amendment to Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended, effective as of August 7, 2026. | Form 8-K12B(Exhibit 10.2) | 8/7/2026 | 001-37627 | |
| 10.3 | Wave Life Sciences, Inc. Amended and Restated 2021 Equity Incentive Plan, effective as of August 7, 2026. | Form 8-K12B(Exhibit 10.3) | 8/7/2026 | 001-37627 | |
| 10.4 | Amendment to the Wave Life Sciences, Inc. Nasdaq Inducement Restricted Stock Unit Award Grant Notice and Nasdaq Inducement Restricted Stock Unit Agreement, effective as of August 7, 2026. | Form 8-K12B(Exhibit 10.4) | 8/7/2026 | 001-37627 | |
| 10.5 | Amendment to the Wave Life Sciences, Inc. Nasdaq Inducement Non-qualified Stock Option Grant Notice and Nasdaq Inducement Non-qualified Stock Option Agreement, effective as of August 7, 2026. | Form 8-K12B(Exhibit 10.5) | 8/7/2026 | 001-37627 | |
| 10.6 | Amended and Restated Wave Life Sciences, Inc. 2019 Employee Stock Purchase Plan, effective as of August 7, 2026. | Form 8-K12B(Exhibit 10.6) | 8/7/2026 | 001-37627 | |
| 10.7 | Form of Non-qualified Stock Option Agreement under the Amended and Restated 2021 Equity Incentive Plan, effective as of August 7, 2026. | Form S-8 POS(Exhibit 99.4.1) | 8/10/2026 | 333-291409 | |
| 10.8 | Form of Restricted Stock Unit Agreement under the Amended and Restated 2021 Equity Incentive Plan, effective as of August 7, 2026. | Form S-8 POS(Exhibit 99.6.1) | 8/10/2026 | 333-291409 | |
| 10.9 | Form of Non-qualified Stock Option Agreement for UK Participants under the Amended and Restated 2021 Equity Incentive Plan, effective as of August 7, 2026. | Form S-8 POS(Exhibit 99.7.1) | 8/10/2026 | 333-291409 | |
| 10.10 | Form of Restricted Stock Unit Agreement for UK Participants under the Amended and Restated 2021 Equity Incentive Plan, effective as of August 7, 2026. | Form S-8 POS(Exhibit 99.7.2) | 8/10/2026 | 333-291409 | |
| 10.11 | Assignment, Assumption and Amendment to Share Purchase Agreement by and between Wave Life Sciences, Inc. and C.P. Pharmaceuticals International C.V., dated as of August 7, 2026. | X | |||
| 10.12 | Amended and Restated Open Market Sale AgreementSM, dated as of August 7, 2026, by and between Wave Life Sciences, Inc. and Jefferies LLC. | POSASR(Exhibit 1.2) | 8/10/2026 | 333-283122 | |
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer | X | |||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer | X | |||
| 32* | Section 1350 Certifications of Principal Executive Officer and Principal Financial Officer | X | |||
| 101.INS | Inline XBRL Instance Document – The instance document does not appear in the interactive data file because its Inline XBRL tags are embedded within the Inline XBRL document | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | X |
(*) The certifications attached as Exhibit 32 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Wave Life Sciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| WAVE LIFE SCIENCES, INC. | ||
| Date: October 27, 2026 | By: | /s/ Paul B. Bolno, M.D., MBA |
|---|---|---|
| Paul B. Bolno, M.D., MBA | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: October 27, 2026 | By: | /s/ Kyle Moran, CFA |
| Kyle Moran, CFA | ||
| Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.